Mercier Johanna, Chief Communications and Corporate Affairs Officer at Gilead Sciences (GILD), has filed 66 Form 4 transactions across two companies, with a clear sell bias. Her total open-market sales reached $21.7 million, while she recorded zero open-market purchases. The recent activity, spanning September 2025 through September 2026, shows 15 sales with no buys, concentrated in GILD stock.
The largest transactions came in clusters. On August 17, 2026, she sold GILD shares worth $1.58 million and $2.27 million, following option exercises valued at $136,722 and $1.54 million. On May 15, 2026, she executed four sales totaling roughly $3.68 million, paired with a $1.67 million option exercise. Smaller sales occurred monthly, including $422,880 on April 15, $432,690 on March 16, and a series of three sales on September 15, 2026, worth $87,174, $115,565, and $229,906. She also had shares withheld for tax purposes in June and September, valued at $162,904 and $195,059, which are automatic transactions rather than discretionary decisions.
The pattern is consistent: sales follow option exercises or restricted stock vesting, with no open-market buying at any point. The only non-GILD activity was a zero-value grant and option exercise at Neurocrine Biosciences (NBIX) in May 2026, which are compensation events rather than trades. The data shows a steady monetization of GILD equity over the past year, with the most recent filing on September 15, 2026, continuing that trend.
AI-assisted summary